Quantcast

Experimental Alzheimer’s Drug Shows Some Potential: Threat from Gammagard Remains

September 24, 2012

On August 24th, 2012 BusinessWeek reported that Elli Lilly´s experimental new drug for the treatment of Alzheimer´s disease delayed the worsening of mental loss, in a sub-analysis of patients in the earliest stage of the disease, while failing to meet the primary goals of two large trials. The only other therapy in final-stage testing is Baxter International Inc.´s Gammagard, an intravenous solution that is made from human plasma. At the end of February 1994, Baxter announced it was removing Gammagard from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Gammagard severe adverse events. [http://www.attorneyone.com/gammagard-lawsuits/

San Diego, CA (PRWEB) September 24, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Gammaguard side effects. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

On August 24th, 2012 BusinessWeek reported that Elli Lilly´s experimental new drug for the treatment of Alzheimer´s disease delayed the worsening of mental loss in a sub-analysis of patients in the earliest stage of the disease, while failing to meet the primary goals of two large trials. As reported, the drug didn´t succeed in restoring memory, thinking or daily activities in any of the groups studied.

The only other therapy in final-stage testing is Baxter International Inc.´s Gammagard, an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body to maintain immunity and fight disease. Gammagard is used to treat primary immune deficiency disorders, and to reduce the risk of infection in individuals with poorly functioning immune systems including those with chronic lymphocytic leukemia. At the end of February 1994, Baxter announced it was removing it from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe adverse events from Gammagard, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Gammagard remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In August 2012, Baxter announced that it will discontinue manufacturing Gammagard S/D [Immune Globulin Intravenous (Human)] as of December 2012, as reported by the Immune Deficiency Foundation.

If you have recently been diagnosed with Hepatitis C and you took Gammagard, you might be able to file a Gammagard lawsuit.

AttorneyOne.com has further information on Gammagard lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/9/prweb9897679.htm.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9916972.htm


Source: prweb



comments powered by Disqus